argenx SE (ARGX)
605.92
+9.18
(+1.54%)
USD |
NASDAQ |
Nov 22, 16:00
597.01
-8.91
(-1.47%)
Pre-Market: 20:00
argenx Revenue (Quarterly): 573.24M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 573.24M |
| June 30, 2024 | 477.64M |
| March 31, 2024 | 401.00M |
| December 31, 2023 | 406.84M |
| September 30, 2023 | 329.79M |
| June 30, 2023 | 270.55M |
| March 31, 2023 | 219.14M |
| December 31, 2022 | 174.16M |
| September 30, 2022 | 137.98M |
| June 30, 2022 | 75.19M |
| March 31, 2022 | 23.41M |
| December 31, 2021 | 26.02M |
| September 30, 2021 | 0.857M |
| June 30, 2021 | 312.24M |
| March 31, 2021 | 158.16M |
| December 31, 2019 | 21.28M |
| September 30, 2019 | 7.686M |
| June 30, 2019 | 8.559M |
| March 31, 2019 | 40.94M |
| December 31, 2018 | 1.422M |
| September 30, 2018 | 2.444M |
| June 30, 2018 | 13.84M |
| Date | Value |
|---|---|
| March 31, 2018 | 6.867M |
| December 31, 2017 | 10.32M |
| September 30, 2017 | 7.693M |
| June 30, 2017 | 18.56M |
| March 31, 2017 | 7.116M |
| December 31, 2016 | 3.677M |
| September 30, 2016 | 5.505M |
| June 30, 2016 | 3.780M |
| March 31, 2016 | 2.511M |
| December 31, 2015 | 1.889M |
| September 30, 2015 | 2.567M |
| June 30, 2015 | 1.727M |
| March 31, 2015 | 1.310M |
| December 31, 2014 | 1.781M |
| September 30, 2014 | 2.009M |
| June 30, 2014 | 0.3087M |
| March 31, 2014 | 0.469M |
| December 31, 2013 | 0.9344M |
| September 30, 2013 | 1.672M |
| June 30, 2013 | 0.5306M |
| March 31, 2013 | 0.5596M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.857M
Minimum
Sep 2021
573.24M
Maximum
Sep 2024
225.47M
Average
196.65M
Median
Revenue (Quarterly) Benchmarks
| Biodexa Pharmaceuticals PLC | -- |
| uniQure NV | 2.287M |
| ProQR Therapeutics NV | 4.227M |
| Akari Therapeutics PLC | -- |
| Merus NV | 11.77M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 91.41M |
| Total Expenses (Quarterly) | 557.07M |
| EPS Diluted (Quarterly) | 1.39 |
| Enterprise Value | 33.13B |
| Gross Profit Margin (Quarterly) | 89.70% |
| Profit Margin (Quarterly) | 15.95% |
| Earnings Yield | -0.14% |
| Normalized Earnings Yield | -0.26 |